The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Note Expiry date 2027-01-01
-Name IAS
-Number 1
-IssueDate 2025-01-01
-Paragraph 112
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard
-URIDate 2025-03-27

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard
-URIDate 2025-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2025-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2025-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard
-URIDate 2025-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Note Effective 2027-01-01
-Name IFRS
-Number 19
-IssueDate 2025-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard
-URIDate 2025-03-27

This amount represents the information of invoiced to counterparty.

No definition available.

This amount represents the information of invoiced to counterparty for additional payment.

No definition available.

This amount represents the information of invoiced to counterparty for initial payment.

No definition available.

Represents the estimated amount payable under the agreement.

No definition available.

Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.

No definition available.

Represents the amount of milestone payment receivable in license and collaboration agreements.

No definition available.

Value of credit note recognized during the period under license and collaborative arrangement.

No definition available.

Amount received by the entity from licensing and collaborative arrangements, attributable to withholding taxes.

No definition available.

Number of active clinical sites in NATiV3 trial.

No definition available.

Represents the number of days of the Phase I trial of lanifibranor.

No definition available.

Represents the number of participants Phase 1 trial of lanifibranor.

No definition available.

Number of shares per depositary receipt.

No definition available.

Represents the number of subjects randomized.

No definition available.

The amount paid on licensing arrangements.

No definition available.

Restructuring and related costs, planned workforce reduction.

No definition available.